EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions

Samer Al Hadidi iD, Adeel M Khan, Aimaz Afrough, Larry D Anderson

The Oncologist · 08.05.2026 · 31 (6)

DOI: 10.1093/oncolo/oyag165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 28.04.2026. Verfasst von Samer Al Hadidi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma, Waldenstrom's, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT So…. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Myeloma, Waldenstrom's, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390-8565, United States.

ORCID-Profile: Samer Al Hadidi

Zitieren

APA

Al Hadidi, S., Khan, A. M., Afrough, A., & Anderson, L. D. (2026). BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag165

Vancouver

Al Hadidi S, Khan AM, Afrough A, Anderson LD. BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag165

BibTeX
@article{AlHadidi2026,
  author = {Al Hadidi, Samer and Khan, Adeel M and Afrough, Aimaz and Anderson, Larry D},
  title = {BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {6},
  doi = {10.1093/oncolo/oyag165}
}
Kostenlos starten →